Skip to main content

Research News

pharma courses

 

gpat

  • How healthy microbes in infancy reduce diabetes risk

    Exposure to antibiotics during a key developmental window in infancy can stunt the growth of insulin-producing cells in the pancreas and may boost risk of diabetes later in life, new research in mice suggests. The study, published this month in the journal Science, also pinpoints specific microorganisms that may help those critical cells proliferate in early life.
  • mRNA-based COVID-19 vaccines train the ‘long-term memory’ of the immune system
    Researchers at the University of Cologne have discovered that mRNA-based COVID-19 vaccines have a persistent effect on the innate immune system. These mechanisms may help the human body to better protect itself against potential future infections / publication in Molecular Systems Biology
  • Growing Body of Evidence Links HPV with Heart Disease
    In addition to causing several types of cancer, human papillomavirus appears to bring a significantly increased risk of heart disease and coronary artery disease, according to a study being presented at the American College of Cardiology's Annual Scientific Session.
  • New Evidence Links Microplastics with Chronic Disease

    Tiny fragments of plastic have become ubiquitous in our environment and our bodies. Higher exposure to these microplastics, which can be inadvertently consumed or inhaled, is associated with a heightened prevalence of chronic noncommunicable diseases, according to new research being presented at the American College of Cardiology's Annual Scientific Session (ACC.25).

  • Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer
    Innovent Biologics, Inc , a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI354
  • Treating chronic inflammatory diseases with JAK inhibitors
    Janus kinase inhibitors are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohns disease or ulcerative colitis. Since their approval, the indications for these medical drugs have steadily increased, but recently safety concerns have also been raised.
  • Scientists discover how to reactivate cancer’s molecular “kill switch”
    Alternative RNA splicing is like a movie editor cutting and rearranging scenes from the same footage to create different versions of a film. By selecting which scenes to keep and which to leave out, the editor can produce a drama, a comedy, or even a thriller—all from the same raw material. Similarly, cells splice RNA in different ways to produce a variety of proteins from a single gene, fine-tuning their function based on need. However, when cancer rewrites the script, this process goes awry, fueling tumor growth and survival.
  • Meningococcal Vaccine Found to be Safe and Effective for Infants in Sub-Saharan Africa
    University of Maryland School of Medicine researchers helped conduct an important new global health study that found a vaccine that protects against five strains of meningitis prevalent in sub-Saharan Africa is safe and effective for use in young children beginning at 9 months of age.
  • Lighting the Way : How Activated Gold Reveals Drug Movement in the Body
    Tracking targeted drug delivery is often a challenge due to limitations in the current imaging techniques. A recent study by Tokyos Waseda University, reports a breakthrough imaging technique that allows direct and highly sensitive tracking of gold nanoparticles inside the body.
  • Targeted Alpha Therapy : A Breakthrough in Treating Refractory Skin Cancer
    Metastatic melanoma, also known as stage IV melanoma, is a type of skin cancer that spreads to other parts of the body. It is one of the most aggressive forms of skin cancer, with current therapies—including immunotherapy and targeted drugs—showing limited effectiveness.
Subscribe to Research News